Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for Robert J. Hayden, Jr.�
1.82
-0.02 (-1.09%)
Apr 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.76 - 1.88
52 week 1.76 - 3.79
Open 1.88
Vol / Avg. 259,101.00/419,978.00
Mkt cap 113.32M
P/E     -
Div/yield     -
EPS -1.17
Shares 62.26M
Beta 1.06
Inst. own 65%
May 5, 2014
Q1 2014 Amicus Therapeutics, Inc. Earnings Release (Estimated) Add to calendar
Apr 9, 2014
Amicus Therapeutics, Inc. at Needham Life Sciences Conference
Mar 4, 2014
Amicus Therapeutics, Inc. at Cowen Health Care Conference
Mar 3, 2014
Q4 2013 Amicus Therapeutics, Inc. Earnings Conference Call
Mar 3, 2014
Q4 2013 Amicus Therapeutics, Inc. Earnings Release
Feb 24, 2014
Amicus Therapeutics, Inc. at Canaccord Genuity Orphan Drug One-on-One Day
Feb 13, 2014
Amicus Therapeutics, Inc. at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -3776.85% -16427.82%
Operating margin -4873.46% -17680.72%
EBITD margin - -16521.76%
Return on average assets -49.91% -50.19%
Return on average equity -135.89% -103.74%
Employees 112 -
CDP Score - -

Address

1 Cedar Brook Drive
CRANBURY, NJ 08512
United States - Map
+1-609-6622000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amicus Therapeutics, Inc. (Amicus) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. It is focused on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy (ERT). Its approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein. Amicus is also conducting preclinical studies on the use of its pharmacological chaperone technology to treat Parkinson�s disease, with an initial focus on Parkinson�s disease patients who are also Gaucher disease carriers.

Officers and directors

John F. Crowley JD Chairman of the Board, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Bradley L. Campbell Chief Operating Officer
Age: 38
Bio & Compensation  - Reuters
Joan C. Winterbottom Senior Vice President - Human Resources
Age: 55
Bio & Compensation  - Reuters
Enrique Dilone Ph.D. Vice President - Technical Operations
Age: 46
Bio & Compensation  - Reuters
Peter M. Macaluso Vice President, General Counsel, Secretary
Age: 37
Bio & Compensation  - Reuters
Jeffrey P. Castelli Ph.D., Vice President - Program and Portfolio Management
Age: 41
Bio & Compensation  - Reuters
Jayne Gershkowitz Vice President - Patient Advocacy & Public Policy
Age: 56
Bio & Compensation  - Reuters
John R. Kirk Vice President - Regulatory Affairs
Age: 56
Bio & Compensation  - Reuters
Kenneth W. Peist Esq. Vice President - Intellectual Property
Age: 49
Bio & Compensation  - Reuters